

ALNYLAM PHARMACEUTICALS, INC.

Form 8-K

March 17, 2006

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

**FORM 8-K
CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 16, 2006

Alnylam Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

000-50743

77-0602661

(State or Other Juris-
diction of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

300 Third Street, Cambridge, MA

02142

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (617) 551-8200

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 1.01. Entry into a Material Definitive Agreement.

Item 9.01. Financial Statements and Exhibits.

SIGNATURE

EXHIBIT INDEX

EX-10.1 First Amendment to Lease, effective as of March 16, 2006

Table of Contents

Item 1.01. Entry into a Material Definitive Agreement.

On March 16, 2006, Alnylam Pharmaceuticals, Inc. (Alnylam) entered into an agreement (the Amendment), effective as of March 16, 2006, with ARE-MA Region No. 28, LLC (the Landlord) amending provisions of the Lease (the Lease), dated as of September 26, 2003, by and between Alnylam U.S., Inc., a wholly-owned subsidiary of Alnylam (the Subsidiary), and the Landlord 's predecessor in interest, Three Hundred Third Street LLC, which Lease relates to the lease of premises located at 300 Third Street, Cambridge, Massachusetts (the Premises), and was assigned by the Subsidiary to Alnylam. The Amendment relates to the lease of additional space at the Premises, as described in the Amendment.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

See Exhibit Index attached hereto.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALNYLAM PHARMACEUTICALS, INC.

Date: March 17, 2006

By: /s/ John M. Maraganore, Ph.D.
John M. Maraganore, Ph.D.
President and Chief Executive Officer

Table of Contents

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
10.1	First Amendment to Lease, effective as of March 16, 2006, by and between Alnylam Pharmaceuticals, Inc. and ARE-MA Region No. 28, LLC and Assignment of Lease, effective as of February 28, 2006, by and between Alnylam Pharmaceuticals, Inc. and Alnylam U.S., Inc.